Evaluation of lipid profile in patients with type II diabetes mellitus on different treatment

المؤلفون

  • Sahar B.Aziz
  • Sura K. Mohi aldeen
  • Saba K. Chlimeran

DOI:

https://doi.org/10.25130/tjphs.2013.9.2.8.253.261

الملخص

This study was conducted to investigate and evaluate the level of serum lipid profile in type II diabetic patients with different treatment by measuring the level of total cholesterol , triglycerides, LDL cholesterol, HDL cholesterol, fasting plasma glucose and to compare them with the level of non –diabetic and normotensive volunteers selected as control (group 1). Methods: This study included (64) patients with type II diabetes ,and (12)healthy control subjects (group 1). Patients were divided into 4 groups according to their treatment :group 2 (n=12) diabetic patients on diet therapy only; group 3 (n=16) patients on combined treatment with insulin and metformine ,group 4 (n=18) patients on daonil only, group 5 (n=18) on insulin only. Blood samples were obtained from all diabetic patients and control subjects after over night fasting (14-16 hrs) and serum lipid profile, fasting plasma glucose were done for the patients and control. Weight, height & body mass index were calculated according to the equation weight in kg/(height)2 in meter. Result; The result revealed that serum total cholesterol, was significantly raised in diabetic subjects as compared to control. There was no significant difference in serum LDL cholesterol, and serum TG between group 1 and 3, also no significant difference in serum LDL cholesterol, between group 1 and 5. Conclusion: It was concluded that the efficacy of the administration of metformin and insulin simultaneously without negative effects. No changes in serum HDL-C. Thus ,early diagnosis and treatment of dyslipideamia can be used as a preventive measure for the development of cardiovascular disease in type 2 diabetes

التنزيلات

منشور

2023-04-24

كيفية الاقتباس

B.Aziz, S., K. Mohi aldeen, S., & K. Chlimeran, S. (2023). Evaluation of lipid profile in patients with type II diabetes mellitus on different treatment. Tikrit Journal of Pharmaceutical Sciences, 9(2), 253–261. https://doi.org/10.25130/tjphs.2013.9.2.8.253.261